News - PD-L1 negative

Successful treatment of synchronous double lung and colon cancers using immune checkpoint inhibitors. (PubMed, Intern Med)

Subsequent testing revealed high-frequency microsatellite instability (MSI-H) in the colon cancer. These findings highlight the therapeutic potential of combined anti-PD-L1 and anti-CTLA-4 antibodies in the treatment of PD-L1-negative lung and MSI-H colorectal cancers.

2 days ago

Journal • Checkpoint inhibition

MSI (Microsatellite instability)

MSI-H/dMMR • PD-L1 negative

Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population. (PubMed, Cancer Immunol Immunother)

NIC and PC seem to be equally supportable options in the treatment of advanced NSCLC. Further analyses are needed to validate our findings.

3 days ago

Clinical • Retrospective data • Journal • Real-world evidence

PD-L1 (Programmed death ligand 1)

PD-L1 negative

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)

Tumor Location Significantly Correlates With PD-L1 Status in Patients With Small Sized Non-small Cell Lung Cancer. (PubMed, Anticancer Res)

PD-L1 expression status significantly correlated with CTR, histological type and tumor location. This is the first report demonstrating a significant correlation between PD-L1 expression and tumor location in NSCLC. We believe that differences in the cancer microenvironment based on tumor location influence PD-L1 expression status in cancer cells.

4 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1)

PD-L1 expression • PD-L1 negative

PD-L1 IHC 22C3 pharmDx

Recent progress in cadonilimab research for oncology applications. (PubMed, Front Immunol)

However, most signals derive from phase I/II single-arm or small-sample studies with limited follow-up, and no randomized head-to-head trials have yet confirmed superiority over standard PD-1+CTLA-4 approaches. This review summarizes the mechanism of action, structural characteristics, clinical research progress, and future applications of cadonilimab, with the aim of offering a useful reference for research and clinical treatment while promoting its broader application in oncology.

5 days ago

Review • Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1)

PD-L1 expression • PD-L1 negative

Kaitanni (cadonilimab)

Feasibility of [89Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer. (PubMed, J Nucl Med)

A work-up with [89Zr]Zr-atezolizumab immuno-PET is clinically feasible. This molecular imaging-based strategy holds potential as a noninvasive tool to more accurately identify patients with mTNBC who may benefit from immune checkpoint inhibitor therapy.

5 days ago

Journal

PD-L1 (Programmed death ligand 1)

PD-L1 negative

Tecentriq (atezolizumab)

DANUBE : Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer (clinicaltrials.gov)

P3, N=1126, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026

6 days ago

Trial completion date

PD-L1 (Programmed death ligand 1)

PD-L1 underexpression • PD-L1 negative

cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • Imjudo (tremelimumab-actl)

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (clinicaltrials.gov)

P3, N=644, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Nov 2028

7 days ago

Trial completion date

HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)

PD-L1 expression • PD-L1 negative

carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • Datroway (datopotamab deruxtecan-dlnk)

Discrepant CD3+ TILs in PD-L1-Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy. (PubMed, Am J Case Rep)

CONCLUSIONS This case highlights a striking dissociation between TIL density and PD-L1 expression, suggesting that CD3-positive TILs may reflect underlying immune activity not captured by PD-L1 status alone. Our findings emphasize the need to further explore TIL profiling as a complementary biomarker, particularly in patients treated with anti-PD-1/anti-CTLA-4-containing regimens.

8 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)

PD-L1 expression • PD-L1 negative

Opdivo (nivolumab) • Yervoy (ipilimumab)

Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer. (PubMed, Breast)

Adding atezolizumab to the study-chemotherapy in mTNBC improves both PFS and patient-reported quality of life, emotional well-being and symptom control. These findings support continued development of this combination regimen and suggest that baseline quality of life may serve as a useful predictor of immunotherapy benefit.

9 days ago

Journal

PD-L1 (Programmed death ligand 1)

PD-L1 negative

Tecentriq (atezolizumab)

Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. (PubMed, JNCI Cancer Spectr)

The addition of ICIs to perioperative chemotherapy improves pathological and survival outcomes in resectable gastric or GEJ cancers, particularly in PD-L1 positive populations, without increasing grade ≥3 TRAEs. These findings support chemoimmunotherapy as a promising curative strategy.

9 days ago

Retrospective data • Journal

PD-L1 (Programmed death ligand 1)

PD-L1 expression • PD-L1 negative

11d

Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression. (PubMed, Cancer Treat Res Commun)

OS similarly favored PD-L1 negative patients (38.8 vs 31.4 months) with HR 1.53, p = 0.12. In a multivariate analysis controlling for TP53 mutations, PD-L1 positivity was associated with a trend towards reduced response to first line treatment with Osimertinib, as well as toward higher risk of progression and death.

11 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53)

PD-L1 expression • TP53 mutation • EGFR mutation • PD-L1 negative

Tagrisso (osimertinib) • simmitinib (SYHA1817)

14d

Evaluation of immuno-oncologic biomarkers and β-catenin expression in response of hepatocellular carcinomas to immunotherapy. (PubMed, NPJ Precis Oncol)

However, in IO non-exposed tumors, CTNNB1-high expression was associated with improved overall survival (HR = 0.97, 95% CI 0.96-0.98, p < 0.00001). In conclusion, our analysis indicates that expression of PD-L1, CTNNB1, and other molecular markers most associated with IO response in other gastrointestinal malignancies are not directly indicative of such responses in HCC.

14 days ago

Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)

PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • PD-L1 negative